Comparison of commercial dosimetric software platforms in patients treated with 177 Lu‐DOTATATE for peptide receptor radionuclide therapy-Reference-Cited by-同舟云学术

Comparison of commercial dosimetric software platforms in patients treated with 177 Lu‐DOTATATE for peptide receptor radionuclide therapy

Published:2020-07-31 Issue:9 Volume:47 Page:4602-4615
ISSN:0094-2405
Container-title:Medical Physics
language:en
Short-container-title:Med. Phys.

Author:

Mora‐Ramirez Erick¹²³,Santoro Lore⁴,Cassol Emmanuelle¹²⁵⁶,Ocampo‐Ramos Juan C.¹²,Clayton Naomi¹²,Kayal Gunjan¹²⁷,Chouaf Soufiane⁴,Trauchessec Dorian⁴,Pouget Jean‐Pierre⁸,Kotzki Pierre‐Olivier⁴⁸,Deshayes Emmanuel⁴⁸,Bardiès Manuel¹²

Affiliation:

1. Centre de Recherches en Cancérologie de ToulouseUMR 1037 ToulouseF‐31037France

2. INSERMUMR 1037Université Toulouse III Paul Sabatier ToulouseF‐31062France

3. Escuela de Física ‐ CICANUM Universidad de Costa Rica San José11501‐2060Costa Rica

4. Département de Médecine Nucléaire Institut Régional du Cancer de Montpellier MontpellierF‐34298France

5. Département de Médecine Nucléaire Hôpitaux Toulouse ToulouseF‐31059France

6. Faculté de Médecine Rangueil Université Toulouse III Paul Sabatier ToulouseF‐31062France

7. SCK CEN Belgian Nuclear Research Centre Boeretang 200 MolBE‐2400Belgium

8. Institut de Recherche en Cancérologie de Montpellier (IRCM) Inserm U1194 Université de MontpellierInstitut Régional du Cancer de Montpellier (ICM) MontpellierF‐34298France

Funder

Universidad de Costa Rica

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mp.14375

Reference77 articles.

1. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

2. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach

3. Long‐term follow‐up of renal function after peptide receptor radiation therapy with (90)Y‐DOTA(0), Tyr(3)‐octreotide and (177)Lu‐DOTA(0), Tyr(3)‐octreotate;Valkema R;J Nucl Med,2005

4. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

5. Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?;EJNMMI Physics;2024-07-18

2. Dosimetry of [¹⁷⁷Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis;Journal of Nuclear Medicine;2024-07-03

3. An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 3: Contribution from Calculating Absorbed Dose from Time-Integrated Activity;Journal of Nuclear Medicine;2024-07-03

4. Enhancing voxel‐based dosimetry accuracy with an unsupervised deep learning approach for hybrid medical image registration;Medical Physics;2024-05-21

5. Optimization of the number of post-therapeutic planar imaging time points for the most reliable organ and tumour dosimetry in peptide receptor radionuclide therapy;Health and Technology;2024-05-01